1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). Supports multidisciplinary research on HIV vaccine development.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed) HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed) Agency: National Institutes of Health Assistance Listings: 93. 855 -- Allergy and Infectious Diseases Research Last Updated: December 2, 2024 View version history on Grants.
gov The purpose of this Notice of Funding Opportunity (NOFO) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive evaluation of vaccine concepts in non-human primate models may be included.
City or township governments Public and Indian housing authorities Federally recognized Native American tribal governments Special district governments For-profit organizations other than small businesses Nonprofits non-higher education without 501(c)(3) Nonprofits non-higher education with 501(c)(3) Other Native American tribal organizations Independent school districts Private institutions of higher education Public and state institutions of higher education Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grantor contact information See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. File name Description Last updated PAR-24-037-Full-Announcement.
html PAR-24-037 Full Announcement Text Link to additional information https://grants. nih. gov/grants/guide/pa-files/PAR-24-037.
html Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity :
According to the current listing, eligibility includes: Non-profit organizations, universities, and other entities conducting HIV research. Confirm the full requirements in the official notice before applying.
The current listing shows up to $2,500,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was March 13, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article